- Home
- ROIV vs SNN Comparison
ROIV vs SNN Comparison
Compare ROIV & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ROIV | SNN |
|---|---|---|
| Founded | 2014 | 1856 |
| Country | United Kingdom | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.1B | 14.1B |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | ROIV | SNN |
|---|---|---|
| Price | $22.78 | $33.23 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 4 |
| Target Price | $24.31 | ★ $32.83 |
| AVG Volume (30 Days) | ★ 5.9M | 907.9K |
| Earning Date | 02-06-2026 | 02-24-2026 |
| Dividend Yield | N/A | ★ 2.20% |
| EPS Growth | N/A | ★ 59.91 |
| EPS | N/A | ★ 0.56 |
| Revenue | $20,329,000.00 | ★ $5,944,000,000.00 |
| Revenue This Year | N/A | $7.71 |
| Revenue Next Year | $741.42 | $5.23 |
| P/E Ratio | ★ N/A | $28.79 |
| Revenue Growth | N/A | ★ 5.35 |
| 52 Week Low | $8.73 | $23.91 |
| 52 Week High | $23.91 | $38.79 |
Technical Indicators
Market Signals| Indicator | ROIV | SNN |
|---|---|---|
| Relative Strength Index (RSI) | 56.31 | 51.59 |
| Support Level | $22.50 | $32.09 |
| Resistance Level | $23.20 | $33.28 |
| Average True Range (ATR) | 0.75 | 0.62 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 63.73 | 57.76 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About SNN Smith & Nephew SNATS Inc.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.